SARS-CoV-2 seroprevalence and COVID-19 vaccination coverage in two states of Nigeria from a population based household survey

dc.contributor.authorEnyereibe, Nwachukwu William
dc.contributor.authorIlori, Elsie
dc.contributor.authorSteinhardt, Laura
dc.contributor.authorStafford, Kristen
dc.contributor.authorDan-Nwafor, Chioma
dc.contributor.authorOchu, Chinwe Lucia
dc.contributor.authorIbrahim, Dalhatu
dc.contributor.authorAlagi, Matthias
dc.contributor.authorIbrahim, Baffa Sule
dc.contributor.authorIwara, Iwara Emem
dc.contributor.authorMba, Nwand
dc.contributor.authorIbrahim, Zainab
dc.contributor.authorAhmed, Rabiatu Aliyu
dc.contributor.authorBotson, Iliya
dc.contributor.authorOgbonna, Stanley Uche
dc.contributor.authorIgumbor, Ehimario Uche
dc.contributor.authorAbubakar, Jafiya
dc.contributor.authorAhmed, Nasir
dc.contributor.authorNwiyi, Gloria Ogochukwu
dc.contributor.authorIhemeje, Chima Emmanuel
dc.contributor.authorOkoi, Catherine
dc.contributor.authorJohn, Doris
dc.contributor.authorAshikeni, Matthew
dc.contributor.authorMuhammad, Basheer Lawan
dc.contributor.authorIriemenam, Nnaemeka C.
dc.contributor.authorOkunoye, Olumide
dc.contributor.authorGreby, Stacie M.
dc.contributor.authorBassey, Orji
dc.contributor.authorOkoye, Mcpaul
dc.contributor.authorBlanco, Natalia
dc.contributor.authorMitchell, Andrew
dc.contributor.authorIpadeola, Oladipupo
dc.contributor.authorAntonza, Gladys S.
dc.contributor.authorMpamugo, Augustine
dc.contributor.authorMakava, Favour
dc.contributor.authorCharurat, Manhattan
dc.contributor.authorAdebajo, Sylvia
dc.contributor.authorSwaminathan, Mahesh
dc.contributor.authorIfedayo, Adetifa
dc.contributor.authorIhekweazu, Chikwe
dc.date.accessioned2025-09-12T08:31:22Z
dc.date.available2025-09-12T08:31:22Z
dc.date.issued2025-08
dc.descriptionDATA AVAILABILITY : The data from this survey are owned by the Nigeria Centre for Disease Control and Prevention. Deidentified survey data and qualitative laboratory results are available upon request from the NCDC after approval of a proposal with a signed data access agreement. The data for this study is available and can be made available on request to the Research Governance Unit of the NCDC through the Corresponding Author.
dc.description.abstractSARS-CoV-2 population-based seroprevalence surveys are useful for estimating the extent of SARS-CoV-2 infections, which may be underestimated by COVID-19 case counts. Surveys conducted in October 2020 in four Nigerian states showed that SARS-CoV-2 seroprevalence ranged from 9.3% in Gombe (northeast) to 25.2% in Enugu (southeast) after the first COVID-19 wave, more than 100 and 700 times higher than the official number of COVID-19 cases in these two states, respectively. We conducted a serosurvey after the second COVID-19 wave to evaluate the extent of SARS-CoV-2 infections, attitudes to COVID-19 vaccines, and COVID-19 vaccination coverage in two regions of Nigeria. Using the World Health Organization (WHO) Unity protocol, 34 enumeration areas (EAs) each in the Federal Capital Territory (FCT) (Northcentral Zone) and Kano State (Northwest Zone) were sampled in June 2021, using probability proportional to estimated size; 20 households in one EA were randomly selected. All consenting and assenting members of a household were asked about risk behaviors; adults who were 18 years and above (the eligible population for COVID-19 vaccination in Nigeria) responded to questions on COVID-19 vaccine attitudes and receipt. Blood and nasal/oropharyngeal samples were taken from all consenting and assenting household members. Blood samples collected were tested with the Luminex xMAP® SARS-CoV-2 Multi-Antigen IgG Assay and swabs by reverse-transcriptase-PCR (RT-PCR). Overall response rates were 76.8% in the FCT (n = 1,505 blood draws) and 80.4% in Kano State (n = 2,178 blood draws). Following the second COVID-19 wave in Nigeria, more than 40% of residents in the FCT (40.3%, 95% CI: 34.7–45.9) and Kano State (42.6%, 95% CI: 39.4–45.8) had evidence of prior SARS-CoV-2 infection. There were no active SARS-CoV-2 infections detected by RT-PCR in either the FCT or Kano State. In the FCT and Kano State, 3.4% and 1.6% of people surveyed reported receipt of any COVID-19 vaccine, three months after vaccines were available in country. In the FCT, 77.5% of adults were aware of COVID-19 vaccines, of whom 46.9% reported willingness to receive them. In Kano State, 48.7% of adults were aware of COVID-19 vaccines, of whom 61.1% were willing to receive them. In both regions, about 84% of those reporting unwillingness to accept COVID-19 vaccines cited concerns over vaccine safety. “Serosurvey findings revealed that SARS-CoV-2 infection was far more widespread in both the Federal Capital Territory and Kano State than indicated by reported case numbers. Despite high awareness, COVID-19 vaccine uptake remained low, primarily due to concerns about vaccine safety. These results highlight the urgent need for targeted risk communication to address vaccine hesitancy and improve coverage. Serosurveys provide valuable insights that can guide public health interventions and future pandemic preparedness in Nigeria.”
dc.description.departmentSchool of Health Systems and Public Health (SHSPH)
dc.description.librarianhj2025
dc.description.sdgSDG-03: Good health and well-being
dc.description.sponsorshipThe United States Center for Disease Control and Prevention.
dc.description.urihttps://www.nature.com/srep
dc.identifier.citationEnyereibe, N.W., Ilori, E., Steinhardt, L. et al. SARS-CoV-2 seroprevalence and COVID-19 vaccination coverage in two states of Nigeria from a population based household survey. Scientific Reports 15, 29272 (2025). https://doi.org/10.1038/s41598-025-14253-z.
dc.identifier.issn2045-2322 (online)
dc.identifier.other10.1038/s41598-025-14253-z
dc.identifier.urihttp://hdl.handle.net/2263/104308
dc.language.isoen
dc.publisherNature Research
dc.rights© The Author(s) 2025. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License.
dc.subjectCOVID-19 pandemic
dc.subjectSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
dc.subjectCoronavirus disease 2019 (COVID-19)
dc.subjectNigeria
dc.subjectSeroprevalence
dc.subjectVaccination
dc.titleSARS-CoV-2 seroprevalence and COVID-19 vaccination coverage in two states of Nigeria from a population based household survey
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Enyereibe_SARSCoV2_2025.pdf
Size:
1.48 MB
Format:
Adobe Portable Document Format
Description:
Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: